Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease

British Journal of Clinical Pharmacology

Volumn 79, Issue 3, 2015, Pages 492-500

  Leaker, Brian R ^a   Barnes, Peter J ^b   Jones, C Richard ^a   Tutuncu, Ahmet ^c   Singh, Dave ^d  

^a RESPIRATORY CLINICAL TRIALS LTD   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c Elevation Pharmaceuticals Inc   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

COPD; EP 101; glycopyrrolate; LAMA; muscarinic antagonist; nebulizer

Indexed keywords

GLYCOPYRRONIUM BROMIDE; PLACEBO; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEART RATE; HUMAN; LUNG FUNCTION; MALE; MEDICAL NEBULIZER; PRIORITY JOURNAL; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN INJURY; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MIDDLE AGED; NEBULIZER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, INHALATION; ADULT; AGED; BLOOD PRESSURE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EQUIPMENT DESIGN; FEMALE; GLYCOPYRROLATE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84930009126     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12517     Document Type: Article

References (43)

1. Gross NJ,. Anticholinergic agents in COPD. Chest 1987; 91: 52S-57.
2. Barnes PJ,. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004; 117 (Suppl. 12A): 24S-32S.
3. Koarai A, Traves SL, Fenwick PS, Brown SM, Chana KK, Russell RE, Nicholson AG, Barnes PJ, Donnelly LE,. Expression of muscarinic receptors by human macrophages. Eur Respir J 2012; 39: 698-704.
4. Haddad EB, Patel H, Keeling JE, Yacoub MH, Barnes PJ, Belvisi MG,. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol 1999; 127: 413-420.
5. Baxter Healthcare Corporation. Robinul® Injection [Package Insert]. Deerfield, IL: Baxter Healthcare Corporation, 2006.
6. NDA 17-558 Pharmacology Review: FDA centre for drug evaluation and research. 1974.
7. van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T,. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010; 65: 1086-1091.
8. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET,. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
9. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC,. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
10. Tutuncu A, Leaker B, Singh D,. Dose-ranging study to assess the safety and pharmacokinetic profile of nebulized glycopyrrolate (EP-101) using high efficiency nebulizer in COPD patients. Am J Respir Crit Care Med 2012; 185: A2914.
11. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2007.
12. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J, Disease GIfCOL. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
13. Donohue JF,. Therapeutic responses in asthma and COPD. Bronchodilators. Chest 2004; 126: 125S-137; discussion 159S-161S.
14. Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M,. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102: 1033-1044.
15. Tashkin DP, Pearle J, Iezzoni D, Varghese ST,. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009; 6: 17-25.
16. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ,. Superiority of 'triple' therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592-598.
17. Hansel TT, Barnes PJ,. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today (Barc) 2002; 38: 585-600.
18. Restrepo RD,. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care 2007; 52: 833-851.
19. Koumis T, Samuel S,. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther 2005; 27: 377-392.
20. Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Harrison S, Gigli PM, Janni A, Geppetti P, Civelli M, Patacchini R,. Pharmacological assessment of the duration of action of glycopyrrolate vs. tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol 2006; 148: 291-298.
21. Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, Barnes PJ,. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005; 128: 1974-1979.
22. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA,. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189: 250-255.
23. Walker FB, Kaiser DL, Kowal MB, Suratt PM,. Prolonged effect of inhaled glycopyrrolate in asthma. Chest 1987; 91: 49-51.
24. Tzelepis G, Komanapolli S, Tyler D, Vega D, Fulambarker A,. Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Eur Respir J 1996; 9: 100-103.
25. Buhl R, Banerji D,. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis 2012; 7: 729-741.
26. Kerwin E, Hébert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D,. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012; 40: 1106-1114.
27. Beeh KM, Singh D, Di Scala L, Drollmann A,. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012; 7: 503-513.
28. Register ECT. EudraCT 2011-003588-31. 2011. Available at https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003588-31/GB (last accessed 9 October 2014).
29. Register ECT. EudraCT 2011-004759-37. 2012. Available at https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004759-37/GB (last accessed 9 October 2014).
30. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D,. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209.
31. Sestini P, Cappiello V, Aliani M, Martucci P, Sena A, Vaghi A, Canessa PA, Neri M, Melani AS, Group AIPOE. Prescription bias and factors associated with improper use of inhalers. J Aerosol Med 2006; 19: 127-136.
32. Rau JL,. Practical problems with aerosol therapy in COPD. Respir Care 2006; 51: 158-172.
33. Hanania NA, Donohue JF,. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc 2007; 4: 526-534.
34. Barta SK, Crawford A, Roberts CM,. Survey of patients' views of domiciliary nebuliser treatment for chronic lung disease. Respir Med 2002; 96: 375-381.
35. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G, Group FiCOPDIS. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-784.
36. Moulton BC, Fryer AD,. Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. Br J Pharmacol 2011; 163: 44-52.
37. Arai N, Kondo M, Izumo T, Tamaoki J, Nagai A,. Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice. Eur Respir J 2010; 35: 1164-1171.
38. Kong KC, Billington CK, Gandhi U, Panettieri RA, Penn RB,. Cooperative mitogenic signaling by G protein-coupled receptors and growth factors is dependent on G(q/11). FASEB J 2006; 20: 1558-1560.
39. Gosens R, Dueck G, Rector E, Nunes RO, Gerthoffer WT, Unruh H, Zaagsma J, Meurs H, Halayko AJ,. Cooperative regulation of GSK-3 by muscarinic and PDGF receptors is associated with airway myocyte proliferation. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1348-1358.
40. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD,. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
41. Kistemaker LE, Oenema TA, Meurs H, Gosens R,. Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci 2012; 91: 1126-1133.
42. Gosens R, Bos IS, Zaagsma J, Meurs H,. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005; 171: 1096-1102.
43. Grainge CL, Lau LC, Ward JA, Dulay V, Lahiff G, Wilson S, Holgate S, Davies DE, Howarth PH,. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 2011; 364: 2006-2015.